Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Summary

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. President and CEO Zachary Hornby, along with CFO Jami Rubin, will represent the company in a fireside chat on June 12 at 3:20 p.m. ET in Miami, FL. The session will be available via live and archived webcast on the company’s website under the 'Events & Presentations' section.

Positive

• Participation in a prestigious conference like the Goldman Sachs 45th Annual Global Healthcare Conference can enhance visibility and investor interest.
• The presence of both the CEO and CFO highlights the significance of the event for the company.
• The discussion will be accessible through live and archived webcasts, increasing transparency and information availability for investors.

Negative

• The press release does not mention any new clinical data or financial updates, which could be seen as a lack of new substantial information for investors.
• There is no indication of immediate financial benefits or partnerships resulting from this participation.

SAN DIEGO--(BUSINESS WIRE)-- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, and Jami Rubin, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference.

The fireside chat session is scheduled for Wednesday, June 12, in Miami, FL, at 3:20 p.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website.

About Boundless Bio

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapy (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. Boundless Bio’s second ecDTx, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical trial in cancer patients with resistance gene amplifications. Leveraging its Spyglass platform, Boundless Bio has additional programs advancing through preclinical development and discovery. Boundless Bio is headquartered in San Diego, CA.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240603162858/en/

Ben Flaum, Boundless Bio

bflaum@boundlessbio.com

Investors

THRUST Strategic Communications

Renee Leck

renee@thrustsc.com

Media

1AB

Dan Budwick

dan@1abmedia.com

Source: Boundless Bio

FAQ

When will Boundless Bio participate in the Goldman Sachs 45th Annual Global Healthcare Conference?

Boundless Bio will participate on June 12 at 3:20 p.m. ET.

Who from Boundless Bio will be present at the Goldman Sachs 45th Annual Global Healthcare Conference?

President and CEO Zachary Hornby and CFO Jami Rubin will represent Boundless Bio.

How can investors access the Boundless Bio session at the conference?

The session will be available via live and archived webcast under the 'Events & Presentations' section of Boundless Bio’s website.

What is Boundless Bio's ticker symbol?

Boundless Bio's ticker symbol is BOLD.

Where is the Goldman Sachs 45th Annual Global Healthcare Conference held?

The conference is held in Miami, FL.